Company Overview

Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies designed to prevent and treat disease by modulating the innate immune system. The company operates within the biotechnology and pharmaceutical research industry, with an emphasis on non-vaccine, non-antiviral approaches to infectious and inflammatory conditions.

The company’s primary value proposition centers on proprietary formulations intended to stimulate localized immune responses, particularly in the respiratory and dermatologic settings. Revelation Biosciences was founded in 2019 and became a publicly traded company through an initial public offering in 2021, listing on Nasdaq under the ticker REVB. Its strategy reflects a targeted approach to early-stage clinical development rather than broad commercial deployment.

Business Operations

Revelation Biosciences operates as a single operating segment focused on biopharmaceutical research and development. The company does not generate material commercial revenue and primarily incurs expenses related to clinical trials, regulatory activities, and research personnel. Its lead development programs include RevTx‑99, an intranasal formulation intended to activate innate immune defenses against respiratory viral infections, and RevTx‑200, a topical program targeting inflammatory skin conditions.

Operations are primarily conducted through internal R&D management with the support of contract research organizations (CROs) and third-party clinical trial service providers. Manufacturing, clinical testing, and regulatory preparation are largely outsourced, which is typical for early-stage biotechnology companies. Data inconclusive based on available public sources regarding any material operating subsidiaries or joint ventures.

Strategic Position & Investments

The company’s strategic direction is focused on advancing its clinical pipeline through early- and mid-stage clinical trials, particularly for indications with large unmet medical needs such as viral respiratory infections. Revelation Biosciences emphasizes rapid, localized immune activation as a potential differentiator compared with systemic antivirals or vaccines.

Capital allocation has been directed almost entirely toward internal pipeline development rather than external acquisitions. No material acquisitions have been disclosed in SEC filings. The company continues to evaluate additional indications and formulations that leverage its core immunologic technology platform. Data inconclusive based on available public sources regarding significant equity investments or portfolio companies.

Geographic Footprint

Revelation Biosciences is headquartered in San Diego, California, a major hub for biotechnology and life sciences research. The company’s executive leadership and core management functions are based in the United States.

Clinical development activities may involve trial sites and research partners in North America and potentially other regions depending on study design, though the company does not report significant permanent international operations. Data inconclusive based on available public sources regarding long-term operational facilities outside the United States.

Leadership & Governance

Revelation Biosciences is led by executives with experience in biotechnology development, regulatory strategy, and corporate finance. The leadership team emphasizes disciplined capital management and focused clinical execution, consistent with the company’s early-stage profile.

• James Rolke – Chief Executive Officer
• Michael Howell – Chief Financial Officer
• Randal J. Van Etten, M.D. – Chief Operating Officer
• Robert “Bo” Cummins – Chief Business Officer

The company is governed by a board of directors responsible for oversight of strategy, risk management, and shareholder interests, in alignment with U.S. public company governance standards.